Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesSafety profile of Tysabri: international risk management plan
Neurological Sciences, 11/25/09
Iaffaldano P et al. – Natalizumab is a monoclonal antibody targeted against alpha–4 integrin that has proved to be very effective in the treatment of MS. It is well tolerated, although severe side effects have been reported that have conditioned its use as a second–line drug for the treatment of MS. The clinical benefit of natalizumab should be weighed carefully against the potential risk of serious adverse events. Therefore, risk management plans have already been developed in order to prevent or minimise risks relating to natalizumab. Data so far obtained from these observational programs confirm the already demonstrated risk–benefit profile of natalizumab in clinical trials.
Related Articles
Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis
Acta Neurologica Scandinavica, 11/23/09
Relevance Score: 69%
APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis
Multiple Sclerosis, 11/19/09
Relevance Score: 69%
Early Psychiatric Manifestation in a Patient with Primary Progressive Multiple Sclerosis
Archives of Iranian Medicine, 11/12/09
Relevance Score: 69%
Cochlear implantation in a profoundly deaf patient who also suffers from multiple sclerosis - a case study
Cochlear Implants International, 10/27/09
Relevance Score: 69%
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Multiple Sclerosis, 10/01/09
Relevance Score: 69%
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety, Tolerability, and Cerebrospinal Fluid Penetration of Ursodeoxycholic Acid in Patients With Amyotrophic Lateral Sclerosis
Clinical Neuropharmacology, 02/09/10
The contribution of disease severity, depression and negative affectivity to fatigue in multiple sclerosis: A comparison with ulcerative colitis
Journal of Psychosomatic Research, 02/08/10
Long-term motor cortex stimulation for amyotrophic lateral sclerosis
Brain Stimulation, 02/08/10
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Levetiracetam in the treatment of neonatal seizures: A pilot study
Seizure - European Journal of Epilepsy, 02/09/10
Safety, Tolerability, and Cerebrospinal Fluid Penetration of Ursodeoxycholic Acid in Patients With Amyotrophic Lateral Sclerosis
Clinical Neuropharmacology, 02/09/10
Article Search
Sponsor
Sponsor